a Numbers in the first row within parentheses are sample numbers
b Stem cell source: BM, bone marrow; PBSC, peripheral blood stem cell; Cord, cord blood
c Donor: MRD, matched related donor; MUD, matched unrelated donor; MMRD, mismatched related donor; MMUD, mismatched unrelated donor
d 2nd cell therapy: donor lymphocyte infusion, stem cell boost or HSCT.
e EFS, event-free survival; OS, overall survival
f MAC, busulfan based conventional myeloablative conditioning; RIC: melphalan based reduced intensity conditioning; RTC: treosulfan based reduced toxicity conditioning; CTX: cyclophosphamide.
g ―, data not available.
REFERENCES
1. Allen CE, Marsh R, Dawson P, et al. Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood. 2018;132(13):1438-1451.
2. Schechter T, Naqvi A, Weitzman S. Risk for complications in patients with hemophagocytic lymphohistiocytosis who undergo hematopoietic stem cell transplantation: myeloablative versus reduced-intensity conditioning regimens. Expert Rev Clin Immunol.2014;10(8):1101-1106.
3. Wustrau K, Greil J, Sykora K-W, et al. Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning. Pediatr Blood & Cancer. 2020.
4. Ali S, Wall DA, M. A, et al. Effect of different conditioning regimens on survival and engraftment for children with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoeitic stem cell transplantation: a single institution experience. Pediatr Blood & Cancer. 2020.
5. Slatter MA, Rao K, Abd Hamid IJ, et al. Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience. Biol Blood Marrow Transplant. 2018;24(3):529-536.
6. Willemsen L, Jol-van der Zijde CM, Admiraal R, et al. Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab.Biol Blood Marrow Transplant. 2015;21(3):473-482.
7. Marsh RA, Kim MO, Liu C, et al. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Biol Blood Marrow Transplant.2013;19(11):1625-1631.
8. Naik S, Eckstein O, Sasa G, et al. Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH. Br J Haematol. 2020;188(6):e84-e87.
9. Vallurupalli M, Berliner N. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood.2019;134(21):1783-1786.
10. Locatelli F, Jordan MB, Allen C, et al. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. N Engl J Med.2020;382(19):1811-1822.
11. Rao K, Adams S, Qasim W, et al. Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen. J Allergy Clin Immunol. 2016;138(4):1152-1160.
12. Furtado-Silva JM, Paviglianiti A, Ruggeri A, et al. Risk factors affecting outcome of unrelated cord blood transplantation for children with familial haemophagocytic lymphohistiocytosis. Br J Haematol.2019;184(3):397-404.